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Edited by Sandro SonninoAbstract Experimental evidence indicates that the mammalian
cell membrane is compartmentalized. A structural feature that
supports membrane segmentation implicates assemblies of se-
lected lipids broadly referred to as lipid rafts. In T-lymphocytes,
lipid rafts are implicated in signalling from the T-cell antigen
receptor (TCR) and in localization and function of proteins
residing proximal to the receptor. This review summarizes the
current literature that deals with lipid raft involvement in T-cell
activation and places particular emphasis in recent studies inves-
tigating lipid rafts in autoimmunity. The potential of lipid rafts
as targets for the development of a new class of immune-modu-
lating compounds is discussed.
 2008 Federation of European Biochemical Societies.
Published by Elsevier B.V.
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The original lipid raft hypothesis proposes the existence of
assemblies of speciﬁc lipids that compartmentalise the plasma
membrane into functionally distinct areas [1–4]. Studies with
model membranes have shown that sphingolipids aggregate
to form microdomains which are stabilized by addition of cho-
lesterol. These self-assembled domains are in liquid ordered
phase and are resistant to solubilisation with non-ionic deter-
gents [5,6]. Likewise, mammalian cells extracted with similar
detergents produce a detergent resistant membrane (DRM)
fraction. DRMs are enriched in sphingomyelin, glyco-
sphingolipids and cholesterol, however, it is debatable as to
whether they reliably correspond to lipid raft domains as they
exist in living cells [7,8]. Microscopy and the ability to observe
diﬀerential membrane condensation using speciﬁc ﬂuorescent
probes provide additional methods which have signiﬁcantly
improved detection of specialized areas in the plasma mem-
brane either before or after cell stimulation [9,10].
The latest results suggest that lipid rafts in non-stimulated
cells are dynamic and of a size too small to detect with conven-
tional microscopy. Various studies have suggested a size as*Corresponding author. Fax: +44 (0) 20 7882 6076.
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doi:10.1016/j.febslet.2008.10.006small as 20 nm and up to 200 nm [11–14]. Despite their small
size, molecules that are thought to partition into rafts show re-
stricted lateral mobility, while proteins that are excluded dif-
fuse freely [15,16]. Upon receptor stimulation, however,
small lipid rafts may coalesce into bigger structures or become
more rigid possibly by associating to the cytoskeleton [17].
Stimulation-induced protein–protein interactions are impor-
tant as they most likely promote microdomain aggregation
[18–20]. However, the prototypical raft model which proposes
that self assembly of certain lipids creates platforms capable of
regulating protein topology and function, is intensely debated
[21–23]. Thus, far the evidence for their existence is suggestive
rather than direct. The publication, in some instances, of
opposing results and skepticism regarding the validity of cer-
tain methods used to describe lipid rafts (summarized in [22])
have tempered initial enthusiasm. Nevertheless, as more re-
ﬁned technologies are developed and new data are incorpo-
rated into existing ones, the intricacies of the lipid raft model
will evolve accordingly. Any alternative theory that is put for-
ward, however, will have to explain the large volume of data
that show the critical role of protein acylation, and of choles-
terol and glycosphingolipid manipulation on cell function.
Biological functions attributed to lipid rafts include endocy-
tosis, pinocytosis, sorting and transport of proteins, and signal
transduction [1,24]. The presence of many key signalling pro-
teins and receptors including Src-family kinases, GTP-binding
proteins and glycosylphosphatidyl-inositol (GPI)-linked recep-
tors into lipid rafts and the potential of these domains to sup-
port protein–protein interactions at the plasma membrane has
attracted many researchers into studying their involvement in
signal transduction across many biological disciplines [1,25–
27]. It is important to note here that for many proteins thought
to localize to lipid rafts, this assignment has often been made
because of their copuriﬁcation with DRMs. Also, following
fractionation, many of these proteins are detected in both
DRM and detergent-soluble fractions (see discussion below
for T-cell lipid rafts). In the text that follows we only concen-
trate on lipid raft function in TCR signalling and activation.2. Structure and signalling by the T-cell antigen receptor
The TCR identiﬁes antigenic peptides presented in the con-
text of cognate Major Histocompatibility Complex (MHC)
proteins expressed on the surface of antigen presenting cells
(APCs). The part of the receptor that recognizes the larged by Elsevier B.V. Open access under CC BY-NC-ND license.
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and b chains. For a subset of T-cells with limited tissue distri-
bution this dimer is composed of the related c and d chains.
The polymorphic dimer closely associates with a cluster of sig-
nal transducing, non-polymorphic proteins named the CD3
complex [28]. The polypeptides that comprise the CD3 com-
plex are c, d, e and f in a stoichiometry of 2e, one of each c
and d and a f homodimer. All CD3 chains contain a signal
transducing motif called ITAM (immunoreceptor tyrosine-
based activation motif) [29,30]. The c, d and e chains contain
one ITAM while f has 3. Therefore, a single TCR is equipped
with 10 ITAMs altogether. The large number of ITAMs is
needed to augment the strength of the signal generated by
the receptor even if only a very small number of stimulatory
antigen/MHC complexes are presented by the APC [31]. Direct
evidence for this premise comes from a recent study. By gener-
ating animals with TCRs that contained variable number of
functional ITAMs, it was shown that reduced number (7 or
less) of functional ITAMs resulted in breakdown of central tol-
erance and development of autoimmune disease. This was due
to incomplete deletion of autoreactive T-cells during develop-
ment, a process that requires intact TCR signaling [32].
Signal transduction by the TCR is initiated by the phosphor-
ylation of the tyrosine residues (Y) within the ITAMs primar-
ily by the Src-family tyrosine kinase Lck [33–35] (Fig. 1). The 2
phospho-Y in each ITAM recruit from the cytosol the ZAP-70
tyrosine kinase which is phosphorylated and activated by Lck
[36]. Activated ZAP-70 propagates transmission of the signal
by phosphorylating the adapter molecule linker for activationTCR
No stimulation
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Fig. 1. A model that correlates changes in the plasma membrane with TCR
and its interaction with lipid rafts is transitory and unable to initiate signalli
results in formation of TCR microclusters and reduces the mobility of lipid ra
Concomitantly, the activity of Lck in lipid rafts increases owing to the actio
changes favour phosphorylation of ITAMs and initiation of signalling.of T-cells (LAT) [37]. LAT is phosphorylated on multiple Y
residues, which then form docking sites for other adapter pro-
teins like SLP-76, Grb-2 and Gads, and enzymes such as PI3K
and PLCc1 [37]. Thus, the central role of LAT in TCR signal-
ling is its capacity when phosphorylated, to form complexes at
the plasma membrane from which a number of signalling cas-
cades originate. Lack of LAT expression uncouples TCR prox-
imal tyrosine phosphorylation from these down-stream
signalling cascades [38].
Like all the members of the Src-family kinases, Lck is regu-
lated by the phosphorylation/dephosphorylation cycle of a C-
terminal Y (Y-505). This Y when phosphorylated by the C-ter-
minal kinase (Csk) associates with the Src homology 2 (SH2)
domain of the molecule inducing a closed conformation,
which has low catalytic activity. Y-505 is dephosphorylated
by the receptor-type tyrosine phosphatase CD45 [39]. Dephos-
phorylation converts Lck into an open form [40]. At this stage
autophosphorylation of another Y within the kinase domain
(Y-394) renders the enzyme fully active [39]. Therefore, the pri-
mary role of CD45 is to prevent deactivation of Lck. Studies of
CD45-null mice and cell lines which show hyperphosphoryla-
tion of Y-505 and impaired TCR signaling conﬁrm the positive
role of CD45 in T-cells [41,42]. Paradoxically, CD45 can also
play a negative role by dephosphorylating Y-394 [43,44]. A re-
cent report addressing this dichotomy has shown that while
low levels of CD45 expression are suﬃcient for Y-505 dephos-
phorylation, high wild type levels of expression were necessary
for Y-394 dephosphorylation and suppression of unwanted
signalling [45].CD45
crocluster
ZAP-70
CD45
TCR
stimulation. In non-stimulated T-cells, the TCR is in monomeric form
ng. Upon antigenic challenge, the reorganization of actin cytoskeleton
fts thus creating an environment conducive to long-lasting interactions.
n of a pool of CD45 molecules that moves to close proximity. These
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signal transducing microclusters. Formation of TCR-rich
microclusters, which also contain activated Lck and ZAP-70,
is the earliest event measured following TCR stimulation
[46,47] (Fig. 1). Pharmacological disruption of actin polymer-
ization inhibited microcluster formation. Interestingly, TCR
microclusters were observed in the presence of a Src-family ki-
nase inhibitor indicating that their formation precedes Lck
activation [46]. It will be important to dissect how the TCR in-
duces actin polymerization independent of Lck activity. The
TCR microclusters subsequently gather in an area in the mem-
brane which is commonly referred to as central supramolecular
activation cluster (cSMAC) [47,48]. This area is part of the
immunological synapse formed between a T-cell and the
APC [49]. Coreceptors and signalling molecules also concen-
trate in the cSMAC, while large glycosylated molecules such
as CD45 and CD43 are excluded [50–52]. It is thought that
the TCR molecules accumulating into the cSMAC do not
transduce signals but are rather destined for endocytosis. How-
ever, newly formed TCR microclusters in the periphery main-
tain signal transmission by recruiting ZAP-70 and SLP-76
[47,53]. Staining of cells with cholera toxin B subunit (CTB),
which binds to raft associated glycosphingolipid GM1, has
shown that lipid rafts accumulate at the IS during T-cell
activation [20,54,55]. Furthermore, the use of membrane inter-
calating ﬂuorescent dyes such as Laurdan and di-4-ANE-
PPDHQ has provided evidence for increased condensation of
the membrane at the site of TCR activation [19,56]. However,
other reports argue against the preferential accumulation of
lipid rafts to the IS [57,58].3. Lipid rafts in TCR signalling and activation
Appropriate spatio-temporal localization of proteins is a key
factor determining signalling activity. Dual acylation is re-
quired for Lck to transmit signals by the TCR [59] and LAT
palmitoylation is important for its function [60]. Since acyla-
tion of proteins frequently determines their localization to cho-
lesterol-sensitive lipid raft domains, these results have been
interpreted as evidence that lipid rafts play a critical role in
TCR signalling by means of the proteins they accrue. This pre-
mise was strengthened by experiments showing that extraction
of cholesterol with chelating agents or treatment of cells with
statins destabilize lipid rafts and modulate signalling [61–64].
The mechanistic model of how lipid rafts could regulate
TCR signalling proposes that signalling starts when the TCRLck
Csk
Csk
Csk
Lime
InactivPAG/CbpUknown Csk
anchor?
Fig. 2. A schematic model for the regulation of Lck activity in T-cells. The
PAG/Cbp, LIME and possibly an additional, as yet unknown, adaptor to the
of lipid rafts with CD45 could result in Y-505 dephosphorylation and increacomes into close proximity with Lck- and LAT-containing
lipid rafts (the size of which is yet to be deﬁned). However,
initiation of signalling should be controlled by receptor
engagement. Such regulation could take place at two levels.
First, at the formation of actin-dependent microclusters as
mentioned earlier [46,47], and second at the upregulation of
the enzymatic activity of a pool of Lck that is in the vicinity
of the TCR. Regarding the ﬁrst level of regulation, Lck-con-
taining lipid rafts should become part of the TCR-rich microcl-
usters, whose initial formation does not require Src-family
kinase activity [46] (Fig. 1). Although this has not been shown
directly, a recent report provides some evidence that shows
clustering of membrane rafts is dependent on actin cytoskele-
ton and that the actin cytoskeleton and cholesterol levels deter-
mine the status of Lck activation [65,66]. Furthermore, single
particle tracking technology revealed that the actin cytoskele-
ton slows down the lateral diﬀusion of acylated Lck in the plas-
ma membrane and thus facilitates accumulation of the kinase
to areas of stimulated TCR clusters [67].
During the second step of control, the activity of the pool of
Lck that gathers to the TCR-microclusters may need to be
transiently increased. This is because Lck was found to be
hyperphosphorylated on Y-505 and to have reduced catalytic
activity in DRMs [68,69]. Csk was present in these prepara-
tions and most likely is responsible for Lck inactivation in
these domains [70]. Inactivation of Lck in lipid rafts might
be required to preserve homeostatic control and to avoid inap-
propriate signalling in the absence of antigenic challenge [27].
Two proteins that bind to Csk were identiﬁed in T-cell DRMs.
These are the Csk-binding protein (Cbp) [71], also known as
PAG [72], and the Lck-interacting molecule (LIME) [73,74],
which are palmitoylated adapter molecules and substrates for
Src-family tyrosine kinases. Cbp is constitutively phosphory-
lated in DRMs [75,76]. Signiﬁcantly, stimulation of the TCR
induced its dephosphorylation and release of Csk [70,72].
These observations led to the hypothesis that Cbp could be
the protein anchor that recruits Csk to the plasma membrane
to inactivate Lck. However, the generation of mutant mice
deﬁcient in Cbp expression has shown that T-cell development
and function remain normal in the absence of Cbp [77],
although this adapter may have an important role as a
tumor–supressor protein [78]. Similarly, LIME knock-out
animals show no overt signs of abnormal T-cell development
and function [79]. Therefore, the search for the plasma mem-
brane Csk-anchor in T-cells is still ongoing, although genera-
tion of Cbp/LIME double knock-out animals may show that
these two adapters have a redundant function in T-cells
(Fig. 2).e Lck
Active Lck
CD45
activity of Lck in lipid rafts is low owing to the recruitment of Csk by
se domains. Movement of Lck out of lipid rafts or transient association
se in Lck activity.
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adjacent to TCR-microclusters could be initiated by CD45-
mediated dephosphorylation of Y-505 (Fig. 1). Although
CD45 is not an integral part of lipid rafts [9,50], upon TCR
triggering, a small fraction may aﬃx to lipid raft domains
[80,81]. This pool of CD45 although small, could be suﬃcient
for Y-505 dephosphorylation [45]. Such movement of CD45 to
lipid rafts could be mediated by binding to raft associated mol-
ecules including CD26 or inﬂuenced by actin polymerization
[82].
Following the initial steps of TCR stimulation many signal-
ling proteins translocate to DRMs and colocalise with lipid
rafts as shown by CTB staining [20,65,83–87]. Furthermore in-
creased condensation of the plasma membrane at the site of
TCR activation [19,56] and on the other hand decreased
TCR signaling in cells loaded with a cholesterol derivative that
inhibits membrane condensation [88], point towards a role for
lipid raft membranes in TCR signalling. However, the exact
size of these microdomains and their detailed mechanism of
action remain undeﬁned.4. Lipid rafts in autoimmunity: potential drug targets?
An important question arising from the work summarized
above is whether the status/function of lipid rafts is altered
in autoimmune diseases. Elevated cholesterol and GM1 have
been noted in activated T-cells [89,90] and in cells from older
donors [91,92]. Interestingly, peripheral blood T-cells from pa-
tients with the autoimmune disease systemic lupus erythemato-
sus (SLE), contain higher levels of GM1 and cholesterol [93].
These levels gradually revert to normal when the cells are
rested in vitro. This may indicate that T-cells in these patientsLupus T cell membrane
TCR cluster?
Lck
Lck
TCR
Healthy T cell membrane
Lck
Fig. 3. Changes in the membrane of lupus T-cells may associate with their aut
T-cell membrane may result in larger and/or less mobile lipid rafts. This in
higher Lck activity, and changes in the actin cytoskeleton seen in these cellsare continuously activated by autoantigens. A pending
question is whether higher levels of cholesterol and GM1,
and possibly of other lipids, signify only a higher metabolic
rate or whether they induce changes in membrane density
and segmentation. If the latter is true then changes in protein
mobility and function may occur potentially impacting on sig-
nalling homeostasis. Defects in various signalling cascades and
in expression of key molecules have been noted in SLE T-cells
[94–96]. For example, T-cells from patients with active disease
expressed less Lck owing to increased consumption of the
protein [94]. This is reminiscent of what was seen after sus-
tained activation of normal T-cells [83]. In addition, we have
observed higher levels of CD45 in lipid rafts in autoimmune
lymphocytes and stimulation of cells with anti-CD3/CD28-
coated beads revealed faster kinetics of CD45 reorientation
in relation to the cell:bead contact area [93,97]. It will be inter-
esting to investigate the topology and kinetics of CD45 in
autoimmune T-cells in relation to TCR microclusters. These
results suggest that the size of a pool of CD45 within or in
close proximity to lipid rafts could be important for converting
Lck into an active form to support signalling by the TCR
(Fig. 3).
There is evidence for a role for lipid rafts in other autoim-
mune diseases as well. For example, CD4loCD40+ is an auto-
reactive T-cell subpopulation recently identiﬁed to be
expanded in autoimmunity [98]. Survival and expansion of
these cells is dependent on the distribution of the CD40 recep-
tor and its associated signalling complex into lipid rafts [99]. In
neuroinﬂammatory diseases including multiple sclerosis (MS),
there is breach of the blood–brain barrier by inﬂammatory leu-
kocytes [100]. Transmigration of inﬂammatory cells into the
central nervous system requires expression of adhesion
molecules. Proteomic analysis of lipid raft microdomains fromLck
CD45
CD45
phospholipid
Actin cytoskeleton
sphingolipid
cholesterol
oimmune phenotype. The higher cholesterol and GM1 content of lupus
combination with the increased association of CD45 with lipid rafts,
could reduce the threshold for activation.
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expression of which was elevated during neuroinﬂammation
[101]. CD166 was found to have an important role in the trans-
migration of leukocytes from blood to the CNS [101].
Recent studies where levels of raft-forming lipids were al-
tered by pharmacological or other means have shown that
there is a correlation between their level of expression and reg-
ulation of the immune system. For example, it has been shown
recently that sialidases, a group of plasma-membrane-associ-
ated enzymes, play a role in modulating microdomain-associ-
ated glycosphingolipid content and inﬂuencing activation in
T-lymphocytes [102,103]. Interestingly, inhibitors of sialidase,
such as oseltamivir (Tamiﬂu), down-regulated GM1 expres-
sion on the surface of T-cells and reduced cytokine production
in activated T-cells [104].
Interestingly, B-cell depleting anti-CD20 antibodies, such as
rituximab, which are used for the treatment of rheumatoid
arthritis (RA), were shown to induce translocation of CD20
to the lipid raft fraction [105]. This event was crucial for induc-
tion of cell apoptosis and was prevented by cholesterol extrac-
tion and disruption of lipid rafts [106]. Therefore, certain
biologic agents used in the clinic may require intact lipid rafts
to exert their therapeutic function.
The development of statins (inhibitors of 3-hydroxy-3-meth-
ylgluttaryl coenzyme A reductase), which are blockers of cho-
lesterol biosynthesis, have provided an additional tool to
address how reduction of cholesterol aﬀects subcellular target-
ing of proteins and signalling. The use of statins in various
autoimmune conditions has started to provide some interesting
results [107,108]. In experimental autoimmune encephalomy-
elitis (EAE), an animal model of MS, statin treatment reduced
pathogenesis by interfering with leukocyte recruitment, T-cell
activation and cell adhesion (reviewed in [109]). Furthermore,
statin treatment was found to reduce N-methyl-D-aspartate
(NMDA)-induced neuronal damage most likely because it re-
duced NMDA receptor movement to lipid rafts [110]. Also,
statins reduce human blood–brain barrier permeability and
downregulate transmigration of leukocytes [111]. Therefore,
statins may prove to be beneﬁcial in the early stages of MS.
It is unclear however, how statins aﬀect the immune system.
In addition to reducing cholesterol, they interfere with post-
translation modiﬁcation and membrane targeting of signalling
proteins such as several small GTP-binding proteins [112].
These proteins become isoprenylated, a process that depends
on the action of HMG-CoA reductase and mevalonate pro-
duction, and is required for lipid raft targeting. Another action
of statins could be their ability to modify lipid raft structure
and function. Ex vivo treatment of T-lymphocytes from SLE
patients with atorvastatin reduced colocalisation of Lck and
CD45 resulting in less active Lck and reduced production of
the pathogenic cytokines IL10 and IL6 upon stimulation
[63]. In an animal model of acute colitis, simvastatin reduced
the severity of the disease and downmodulated the activity of
the NF-jB pathway in stimulated intestinal epithelial cells
[113]. Furthermore, production of pathogenic chemokines
from intestinal epithelial cells was dependent on cholesterol
suggesting possible involvement of lipid rafts in this process
[114]. Therefore, statins mediate their eﬀects on the immune
system via multiple mechanisms. In certain cases their eﬀect
may be mediated by inducing alterations in lipid rafts and/or
inhibiting targeting of key signalling molecules to these do-
mains. Nevertheless, additional roles for cholesterol and itsmetabolites are becoming apparent. A recent report makes
some progress in unraveling how cholesterol levels aﬀect T-cell
proliferation. Activation of T-cells induced cholesterol synthe-
sis and suppression of its transport, which is mediated by the
LXR (liver X receptor) pathway [115], suggesting that a spe-
ciﬁc pool of cellular cholesterol is important for T-cell prolif-
eration, although its location is unclear.
Polyunsaturated fatty acids (PUFAs) are shown to
intercalate and remodel lipid raft domains [116]. Treatment
of T-lymphocytes with PUFAs resulted in the delocalisation
of raft-anchored signalling proteins such as LAT [117]. LAT
delocalisation was accompanied by its reduced tyrosine phos-
phorylation and IL2 production following TCR stimulation
[118]. PUFAs were also shown to interfere with the formation
of the IS [119]. In addition, cell treatment with dietary ﬁsh oils
altered the structure and size of membrane domains [120] and
reduced signalling by the TCR [121,122]. In an experimental
model of colitis, PUFA administration prevented inﬂamma-
tion-induced exit of tight junction proteins from lipid rafts
and diminished disruption of tight junctions in the intestinal
mucosa [123]. Collectively, these results lay the case for closer
investigation of PUFAs and dietary ﬁsh oils as lipid raft mod-
iﬁers and as beneﬁcial agents in autoimmunity and inﬂamma-
tion.5. Perspectives
Suggestive evidence argues for the involvement of lipid rafts
in autoimmunity. Some existing agents used in the clinic, such
as anti-CD20 antibodies and statins, may exert their
therapeutic eﬀect, at least in part, via lipid rafts. In our view,
there is suﬃcient evidence suggesting that lipid rafts are valid
targets for the development of new pharmaceuticals capable
of modifying their function in autoimmunity. These can be
agents that are either general lipid raft modulators acting on
all cells or speciﬁc for a raft-associated protein with a restricted
pattern of expression. More speciﬁc agents will also serve as
tools to better elucidate the role of lipid raft domains in the
development and pathophysiology of autoimmune diseases.
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